LOS ANGELES, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ:CAPR) a biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics announced today that Linda Marbán, Chief Executive Officer will present at the annual Partnering Forum of the Stem Cell Meeting on the Mesa to be held October 7-9 in La Jolla, California.
| Event: | 2015 Stem Cell Meeting on the Mesa – Partnering Forum | |
| Date: | October 07, 2015 | |
| Time: | 11:45 a.m. PDT | |
| Location: | Estancia La Jolla Hotel & Spa, 9700 North Torrey Pines Road, La Jolla, CA 92037 | |
A live video webcast will be available at: http://stemcellmeetingonthemesa.com/webcast/ with a replay of the webcast to be published on http://capricor.com/news/events/.
Please visit http://stemcellmeetingonthemesa.com/ for full information including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only. This conference brings together senior executives and top decision makers in the industry within the scientific community with the shared goal of advancing and translating cutting-edge research into revolutionary treatments and cures.
About Capricor Therapeutics
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class therapeutics. Our lead programs target post myocardial infarction (heart attack), heart failure and Duchenne Muscular Dystrophy. The Company has two leading product candidates under investigation: CAP-1002, a cardiac cell therapy, and Cenderitide, a natriuretic peptide receptor agonist. CAP-1002 is in development for the treatment of post myocardial infarction (heart attack), advanced heart failure and Duchenne muscular dystrophy associated cardiomyopathy. Cenderitide is in development for the outpatient treatment of heart failure as well as potential other indications. In addition, the Company is conducting research and development on its exosomes platform technology for cardiac diseases and other potential indications. For additional information visit www.capricor.com.